NCT00351234View on ClinicalTrials.gov

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

April 30, 2007

Conditions
Diabetes Mellitus, Type IHypoglycemia
Interventions
DRUG

Carnitine (drug)

Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.

Trial Locations (1)

64108

The Children's Mercy Hospital, Kansas City

Sponsors
All Listed Sponsors
collaborator

Leadiant Biosciences, Inc.

INDUSTRY

collaborator

Minimed Pharmaceuticals

INDUSTRY

collaborator

Pharmacia/Upjohn Career Development Award

UNKNOWN

lead

Children's Mercy Hospital Kansas City

OTHER

NCT00351234 - Carnitine Levels and Carnitine Supplementation in Type I Diabetes | Biotech Hunter | Biotech Hunter